2018 Annual Meeting | C225 - Neuromuscular Junction Disorders I: Myasthenia Gravis, Ocular, and MuSK Myasthenia
| 01:00 PM - 01:05 PM | Luncheon |
Introduction
|
| 01:05 PM - 01:55 PM | Speaker |
Diagnosis of Myasthenia Gravis: Patient Scenarios
Janice M. Massey, MD, FAAN |
| 01:55 PM - 02:45 PM | Speaker |
Treating Myasthenia Gravis in 2018: New Developments and Best Available Evidence
Jeff Guptill, MD, FAAN |
| 02:45 PM - 03:00 PM | Q&A |
Questions and Answers
|
| Laura M. Tormoehlen, MD, FAAN | The institution of Dr. Tormoehlen has received research support from Genentech. Dr. Tormoehlen has received publishing royalties from a publication relating to health care. |
| Janice M. Massey, MD, FAAN | Dr. Massey has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Argenix. Dr. Massey has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Revance Therapeutics. Dr. Massey has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Momenta. The institution of Dr. Massey has received research support from Revance . |
| Jeff Guptill, MD, FAAN | Dr. Guptill has received personal compensation for serving as an employee of argenx. Dr. Guptill has stock in argenx. |